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Robin E. Williamson1Methods of Analyzing Rare Variants
Li and Leal, page 311
The current technologies in use for the identiﬁcation of
genetic variants associated with complex diseases focus
on the concept that common variants are responsible for
a small but signiﬁcant risk effect. An alternative, but non-
exclusive, hypothesis is that multiple rare variants are
responsible for a gene’s association with a phenotype.
These rare variants are more difﬁcult to identify with
methods that are based on linkage disequilibrium and
tSNPs because such variants are less likely to be tagged by
known SNPs in the region. Also, several different rare var-
iants may be present in a single dataset of affected individ-
uals. To deal with these situations, Li and Leal present tech-
niques for identifying association variants in the presence
of high allelic heterogeneity. Their analyses handle se-
quence data that will become increasingly more available
as sequencing technologies improve. The authors compare
the single-marker, multi-marker, and collapsing versions of
their methods and, on the basis of the results of their inves-
tigation, propose a ‘‘combined multivariate and collaps-
ing’’ approach that reaps the beneﬁts of each of the indi-
vidual methods.
Adaptive Evolution of the UGT2B17 CNV
Xue et al., page 337
Copy-number variation (CNV) is recognized as a signiﬁcant
source of variation in humans, and differentiation between
humans and great apes, as well as among subsets of human
populations, suggests that CNV has potentially contrib-
uted to evolutionary processes. To assess whether the pres-
ence of a region of CNV is due to selection versus genetic
drift, Xue et al. decide to evaluate a speciﬁc CNV using
the techniques already established for detecting signatures
of selection at SNPs. The authors choose to study the CNV
containing UGT2B17 because the gene’s involvement in
steroid and xenobiotic metabolismmakes it a strong candi-
date for evolutionary control of gene dosage. Additionally,
the gene resides in a complex region of the genome, and
the analysis of such a region might provide an important
example for the design of CNV-selection studies. Xue
et al. start by re-examining andmodifying the reference as-
sembly to obtain an accurate depiction of the structure of
the UGT2B17 alleles. An analysis of the alleles on a panelof samples from around the world reveals that the deletion
allele is more frequent in the East-Asian populations than
it is in African and European populations. By resequencing
the segments ﬂanking the deletion in the four populations
studied, the authors perform a number of neutrality tests
while taking into account the complexity of the region.
The results of these analyses suggest that the region un-
derwent unique selective events in each of the different
populations.
Gene Therapy for mtDNA-Related Diseases
Ellouze et al., page 373
Although many advancements have been made in the
identiﬁcation of mitochondrial diseases and in the under-
standing of their pathogenesis, treatment of such diseases
is often quite ineffective. One potential therapeutic
method relies on the expression of mitochondrial genes
in the nucleus. This technique, termed allotopic expres-
sion, has recently been optimized for a few genes, and
the successful restoration of mitochondrial function
in vitro has been reported. As the next step toward devel-
oping a means for treating mitochondrial diseases in hu-
mans, Ellouze et al. sought to establish how well allotopic
expression works in an in vivo system. In order to do this,
the authors ﬁrst needed to develop a proper animal model
in which to test their method. Their previous work has fo-
cused on Leber Hereditary Optic Neuropathy (LHON), and
they extend that work here. LHON is the most common
mitochondrial disease, and most cases are due to muta-
tions in ND1, ND4, or ND6. The authors allotopically
express a common mutant variant of ND4 in adult rat
eyes, and evaluation reveals that the treated eyes develop
a LHON phenotype. Subsequent treatment with the wild-
type gene successfully rescues the disease phenotype and
prevents further damage.
DYRK1A Dosage Perturbs REST Levels
Canzonetta et al., page 388
Down syndrome (DS), caused by trisomy of chromosome
21, is characterized by a number of phenotypic features,
and a great deal of work has been done to attribute
each of the disease features to the increased dosage of
speciﬁc regions of chromosome 21. Previous work has
reported that levels of neuron-restrictive silencer factor,1Deputy Editor, AJHG
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encoded by REST, are decreased in Down-syndrome brain
cells. REST is a key regulator of many neuronal functions
and is involved in neuronal differentiation. To further ex-
amine this relationship, Canzonetta et al. evaluate the
level of Rest expression in a transchromosomic mouse
model of DS. They begin by looking at pluripotent mouse
embryonic stem cells, and they report that the expression
of Rest is signiﬁcantly reduced in DS cells in comparison
to transcript levels in wild-type cells. By examining
a number of mouse DS model cell lines, the authors are
able to determine that this effect on Rest levels is due to
a minimal region that contains just three genes. A concur-
rent linkage analysis in humans conﬁrms this candidate
region. Additional analyses allow the authors to deter-
mine that it is the dose of DYRK1A, one of the genes in
the region, that is responsible for the modulations of
REST transcript levels. This relationship between DYRK1A
and the REST pathway might be a crucial mechanism
through which trisomy 21 causes a number of DS neuro-
nal features.
X-linked Dominant Protoporphyria
Whatley et al., page 408
Disruption of one of a number of the genes involved in
heme biosynthesis causes porphyria, or the accumulation298 The American Journal of Human Genetics 83, 297–298, Septemof porphyrins, which leads to cutaneous or neurological
manifestations. Erythropoietic protoporphyria (EPP) is
characterized by life-long photosensitivity and is most of-
ten due to mutations in FECH, the gene encoding the ter-
minal enzyme of heme biosynthesis. However, a signiﬁcant
number of EPP families do not carry mutations in FECH.
Whately et al. study a subgroup of these FECH-mutation-
negative families who each have an unusually high level
of erythrocyte protoporhyrin in its zinc chelate form.
Due to suggestive evidence that this type of EPP is
X-linked, the authors choose to examine two X-chromo-
some genes that are involved in heme formation, GATA1
and ALAS2. One deletion in ALAS2, c.1706-1709delAGTG,
is identiﬁed in six of the families, and a different ALAS2 de-
letion, c.1699-1700delAT, is detected in the remaining two
families. Of note, the delAGTG mutation is found on ﬁve
different haplotypes, suggesting that it has independently
arisen multiple times. ALAS2 is an erythroid-speciﬁc en-
zyme and has been found to be essential for hemoglobin
formation. All previously detected mutations in the gene
are loss-of-function alleles and cause X-linked hereditary
sideroblastic anemia with iron overload. Here, functional
work on the EPP deletion alleles demonstrates that they
cause an increase in ALAS2 activity and suggests that
a gain-of-function mechanism is responsible for the
observed accumulation of protoporphyrin and its zinc
chelate in these EPP families.ber 12, 2008
